X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WYETH LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WYETH LTD DR. REDDYS LAB/
WYETH LTD
 
P/E (TTM) x 26.2 27.7 94.4% View Chart
P/BV x 3.2 5.3 60.3% View Chart
Dividend Yield % 0.8 1.3 64.1%  

Financials

 DR. REDDYS LAB   WYETH LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
WYETH LTD
Mar-13
DR. REDDYS LAB/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs2,7881,044 266.9%   
Low Rs1,902818 232.5%   
Sales per share (Unadj.) Rs860.8298.6 288.3%  
Earnings per share (Unadj.) Rs57.157.2 99.7%  
Cash flow per share (Unadj.) Rs122.058.4 208.9%  
Dividends per share (Unadj.) Rs20.0017.00 117.6%  
Dividend yield (eoy) %0.91.8 46.7%  
Book value per share (Unadj.) Rs757.7249.5 303.7%  
Shares outstanding (eoy) m165.9122.72 730.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.73.1 87.3%   
Avg P/E ratio x41.116.3 252.6%  
P/CF ratio (eoy) x19.215.9 120.6%  
Price / Book Value ratio x3.13.7 82.9%  
Dividend payout %35.029.7 118.0%   
Avg Mkt Cap Rs m389,03421,157 1,838.8%   
No. of employees `00023.50.5 4,781.3%   
Total wages/salary Rs m32,149400 8,037.3%   
Avg. sales/employee Rs Th6,070.813,787.4 44.0%   
Avg. wages/employee Rs Th1,366.6813.0 168.1%   
Avg. net profit/employee Rs Th402.52,643.3 15.2%   
INCOME DATA
Net Sales Rs m142,8106,783 2,105.3%  
Other income Rs m1,552353 440.2%   
Total revenues Rs m144,3627,136 2,023.0%   
Gross profit Rs m23,5121,617 1,453.8%  
Depreciation Rs m10,77227 40,496.2%   
Interest Rs m7886 14,327.3%   
Profit before tax Rs m13,5041,938 696.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m4,380632 692.8%   
Profit after tax Rs m9,4681,301 728.0%  
Gross profit margin %16.523.8 69.1%  
Effective tax rate %32.432.6 99.4%   
Net profit margin %6.619.2 34.6%  
BALANCE SHEET DATA
Current assets Rs m104,9846,984 1,503.2%   
Current liabilities Rs m68,9382,056 3,353.2%   
Net working cap to sales %25.272.6 34.7%  
Current ratio x1.53.4 44.8%  
Inventory Days Days7499 74.9%  
Debtors Days Days10424 432.7%  
Net fixed assets Rs m104,385244 42,728.2%   
Share capital Rs m830227 365.3%   
"Free" reserves Rs m124,8865,441 2,295.4%   
Net worth Rs m125,7165,668 2,218.0%   
Long term debt Rs m25,08925 100,356.0%   
Total assets Rs m225,4437,901 2,853.3%  
Interest coverage x18.1353.3 5.1%   
Debt to equity ratio x0.20 4,524.6%  
Sales to assets ratio x0.60.9 73.8%   
Return on assets %4.516.5 27.5%  
Return on equity %7.522.9 32.8%  
Return on capital %9.734.0 28.5%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m72,62315 477,782.9%   
Fx outflow Rs m18,9162,677 706.6%   
Net fx Rs m53,707-2,662 -2,017.5%   
CASH FLOW
From Operations Rs m18,030923 1,953.0%  
From Investments Rs m-14,883317 -4,696.4%  
From Financial Activity Rs m-4,440-481 923.1%  
Net Cashflow Rs m-1,236759 -162.8%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 7.2 490.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 30.4 50.3%  
Shareholders   75,885 21,978 345.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 14, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS